ACTIVE_NOT_RECRUITING

A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease

Talk to us

Conditions

Inflammatory Bowel DiseasesCrohn's DiseaseUlcerative ColitisIndeterminate ColitisDigestive System Diseases

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

TARGET-IBD is a 5-year, longitudinal, observational study of adult and pediatric patients (age 2 and above) being managed for Inflammatory Bowel Disease (IBD) in usual clinical practice. TARGET-IBD will create a research registry of patients with IBD within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.

Official Title

A 5-year Longitudinal Observational Study of Patients Undergoing Therapy for Inflammatory Bowel Disease

Quick Facts

Study Start:2017-07-24
Study Completion:2026-02
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:ACTIVE_NOT_RECRUITING

Study ID

NCT03251118

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:2 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Adults and children (age 2 or older) with a diagnosis of Crohn's disease (CD), Ulcerative colitis (UC), or Indeterminate colitis (IBDU) having been prescribed any IBD treatment (initial or subsequent) outside of a clinical trial.
  2. 2. Have plans for future visits at the site for continued management of IBD.
  1. 1. Inability to provide written informed consent/assent.
  2. 2. Being enrolled in any interventional study or trial for IBD treatment. Note: Patient may be enrolled in other registries or studies where IBD treatment outcomes are observed and/or reported (such as center-based registries).
  3. 3. Prior total abdominal colectomy for UC or IBDU.

Contacts and Locations

Study Locations (Sites)

Om Research
Lancaster, California, 93534
United States
FACEY Medical Foundation
Mission Hills, California, 91345
United States
University of California - Davis
Sacramento, California, 95817
United States
Stanford University
Stanford, California, 94305
United States
University of Colorado Denver
Aurora, Colorado, 80045
United States
Gastro Florida
Clearwater, Florida, 33762
United States
University of Florida Health Jacksonville-Gastroenterology
Jacksonville, Florida, 32207
United States
Advanced Gastroenterology Associates, LLC
Palm Harbor, Florida, 34684
United States
Atlanta Gastro
Atlanta, Georgia, 30342
United States
The University of Chicago Medical Center
Chicago, Illinois, 60637
United States
Indianapolis Gastroenterology Research Foundation
Indianapolis, Indiana, 46237
United States
University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242
United States
Gastroenterology Associates
Baton Rouge, Louisiana, 70809
United States
Louisiana Research Center, LLC
Shreveport, Louisiana, 71105
United States
University of Michigan Medical Center
Ann Arbor, Michigan, 48109
United States
University of Minnesota
Minneapolis, Minnesota, 55454
United States
Saint Louis University
St Louis, Missouri, 63104
United States
University of Nebraska Medical Center
Omaha, Nebraska, 68198
United States
Dartmouth-Hitchcock Medical Center
Lebanon, New Hampshire, 03755
United States
Rutgers, Robert Wood Johnson Medical School
New Brunswick, New Jersey, 08901
United States
NYU Langone Health
New York, New York, 10016
United States
Mount Sinai, Icahn School of Medicine
New York, New York, 10029
United States
Premier Medical Group of the Hudson Valley
Poughkeepsie, New York, 12601
United States
The Children's Hospital at Montefiore
The Bronx, New York, 10467
United States
Cary Gastroenterology Associates
Cary, North Carolina, 27518
United States
University of North Carolina
Chapel Hill, North Carolina, 27599
United States
Carolinas Healthcare System-Center for Digestive Health
Charlotte, North Carolina, 28204
United States
Digestive Health Specialists, PA
Winston-Salem, North Carolina, 27103
United States
Cleveland Clinic/DIgestive Disease and Surgery Institute
Cleveland, Ohio, 44195
United States
The Ohio State University Wexner Medical Center
Columbus, Ohio, 43210
United States
University of Pennsylvania
Philadelphia, Pennsylvania, 19104
United States
Vanderbilt University Medical Center
Nashville, Tennessee, 37232
United States
UT Southwestern
Dallas, Texas, 75390
United States
Baylor College of Medicine
Houston, Texas, 77030
United States
Swedish Medical Center
Seattle, Washington, 98122
United States
MultiCare Institute for Research and Innovation
Tacoma, Washington, 98405
United States
University of Wisconsin Hospital & Clinics
Madison, Wisconsin, 53705
United States

Collaborators and Investigators

Sponsor: Target PharmaSolutions, Inc.

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2017-07-24
Study Completion Date2026-02

Study Record Updates

Study Start Date2017-07-24
Study Completion Date2026-02

Terms related to this study

Keywords Provided by Researchers

  • Crohn's Disease
  • Ulcerative colitis
  • Indeterminate colitis
  • Digestive System Diseases

Additional Relevant MeSH Terms

  • Inflammatory Bowel Diseases
  • Crohn's Disease
  • Ulcerative Colitis
  • Indeterminate Colitis